Ulcerative Colitis Indication Strategy Report 2026: IL-23, JAK1, Trials and Deal Outlook uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Waldenstrom Macroglobulinemia Indication Strategy Report 2026: BTK, CXCR4, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Uveal Melanoma Indication Strategy Report 2026: GNAQ, PKC, Trials and Deal Outlook uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Agenus 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Y-mAbs Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

TScan Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Liquidia 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Tarsus Pharmaceuticals 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Vanda Pharmaceuticals 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Ventyx Biosciences 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Arbutus Biopharma 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

A 2026 Merkel cell carcinoma strategy report covering elderly burden, PD-1 and DLL3 biology, clinical competition, deal signals and portfolio positioning.